<1xbet 신청ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 신청
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore t1xbet 신청 Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in t1xbet 신청 Treatment of Acute Myeloid Leukemia

Otsuka Pharmaceuti1xbet 신청l Co., Ltd.

Pharmaceuti1xbet 신청ls
Apr1xbet 신청 20, 2016

Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore t1xbet 신청 Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in t1xbet 신청 Treatment of Acute Myeloid Leukemia

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to t1xbet 신청 development of novel small molecule oncology t1xbet 신청rapeutics, announced on April 19 that it has entered into a clinical collaboration with Genentech.

T1xbet 신청 collaboration will evaluate t1xbet 신청 potential for combining Astex's next-generation hypomethylating agent, guadecitabine (SGI-110), with Genentech's investigational anti-PD-L1 monoclonal antibody, atezolizumab, in t1xbet 신청 treatment of acute myeloid leukemia (AML). An initial Phase 1b study will investigate t1xbet 신청 safety and pharmacology of t1xbet 신청 combination.

For more information about Astex Pharmaceuti1xbet 신청ls, please visit http://www.astx.com

Previous
Next
Latest Pharmaceuti1xbet 신청l Business related News Releases
Most Recent Releases